CN111320609A - 一种THRβ受体激动剂化合物及其制备方法和用途 - Google Patents

一种THRβ受体激动剂化合物及其制备方法和用途 Download PDF

Info

Publication number
CN111320609A
CN111320609A CN201811527414.4A CN201811527414A CN111320609A CN 111320609 A CN111320609 A CN 111320609A CN 201811527414 A CN201811527414 A CN 201811527414A CN 111320609 A CN111320609 A CN 111320609A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salts
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811527414.4A
Other languages
English (en)
Chinese (zh)
Inventor
余尚海
李本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuozhen Pharmaceutical Co
Original Assignee
Tuozhen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuozhen Co ltd filed Critical Tuozhen Co ltd
Priority to CN201811527414.4A priority Critical patent/CN111320609A/zh
Priority to CN202511225496.7A priority patent/CN121081472A/zh
Priority to HRP20260358TT priority patent/HRP20260358T1/hr
Priority to PE2025001790A priority patent/PE20252338A1/es
Priority to CN202310453989.0A priority patent/CN116444498B/zh
Priority to TW113107718A priority patent/TWI899867B/zh
Priority to ES19896475T priority patent/ES3064255T3/es
Priority to EP25157448.9A priority patent/EP4574821B8/en
Priority to PT198964751T priority patent/PT3893889T/pt
Priority to KR1020257028884A priority patent/KR20250133486A/ko
Priority to BR112021010871-8A priority patent/BR112021010871A2/pt
Priority to LTEPPCT/US2019/066013T priority patent/LT3893889T/lt
Priority to JP2021533640A priority patent/JP7532371B2/ja
Priority to TW114133235A priority patent/TW202600541A/zh
Priority to PE2021000858A priority patent/PE20211788A1/es
Priority to MX2021006908A priority patent/MX2021006908A/es
Priority to ARP190103650A priority patent/AR117694A1/es
Priority to US16/712,301 priority patent/US11084802B2/en
Priority to FIEP19896475.1T priority patent/FI3893889T3/fi
Priority to EP19896475.1A priority patent/EP3893889B8/en
Priority to DK19896475.1T priority patent/DK3893889T3/da
Priority to FIEP25157448.9T priority patent/FI4574821T3/fi
Priority to IL310699A priority patent/IL310699B2/en
Priority to AU2019398339A priority patent/AU2019398339C1/en
Priority to PCT/US2019/066013 priority patent/WO2020123827A1/en
Priority to CA3120880A priority patent/CA3120880A1/en
Priority to KR1020217021249A priority patent/KR102905557B1/ko
Priority to CN201980081797.3A priority patent/CN113194958B/zh
Priority to SG11202106194TA priority patent/SG11202106194TA/en
Priority to MA054471A priority patent/MA54471A/fr
Priority to DK25157448.9T priority patent/DK4574821T3/da
Priority to IL283362A priority patent/IL283362B2/en
Priority to TW108145594A priority patent/TWI837244B/zh
Priority to LTEP25157448.9T priority patent/LT4574821T/lt
Priority to EP25157450.5A priority patent/EP4529954A3/en
Priority to MYPI2021002740A priority patent/MY207657A/en
Publication of CN111320609A publication Critical patent/CN111320609A/zh
Priority to US17/013,314 priority patent/US11034676B2/en
Priority to MX2024003295A priority patent/MX2024003295A/es
Priority to CL2021001521A priority patent/CL2021001521A1/es
Priority to CONC2021/0008817A priority patent/CO2021008817A2/es
Priority to US18/315,291 priority patent/US12338232B2/en
Priority to JP2024124269A priority patent/JP2024174860A/ja
Priority to US19/052,553 priority patent/US12365669B2/en
Priority to US19/052,557 priority patent/US12459926B2/en
Priority to AU2025201590A priority patent/AU2025201590A1/en
Priority to US19/319,446 priority patent/US20260001867A1/en
Priority to IL324507A priority patent/IL324507A/en
Priority to JP2025229427A priority patent/JP2026035823A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201811527414.4A 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途 Pending CN111320609A (zh)

Priority Applications (48)

Application Number Priority Date Filing Date Title
CN201811527414.4A CN111320609A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途
CN202511225496.7A CN121081472A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途
HRP20260358TT HRP20260358T1 (hr) 2018-12-13 2019-12-12 Spoj agonist thr-beta receptora i postupak za njegovu proizvodnju kao i njegova uporaba
PE2025001790A PE20252338A1 (es) 2018-12-13 2019-12-12 Compuesto agonista de receptor thrb y metodo de preparacion
CN202310453989.0A CN116444498B (zh) 2018-12-13 2019-12-12 THRβ受体激动剂化合物及其制备方法和用途
TW113107718A TWI899867B (zh) 2018-12-13 2019-12-12 一種THRβ受體激動劑化合物及其製備方法和用途
ES19896475T ES3064255T3 (en) 2018-12-13 2019-12-12 Thrb receptor agonist compound and preparation method and use thereof
EP25157448.9A EP4574821B8 (en) 2018-12-13 2019-12-12 Thrb receptor agonist compound and preparation method and use thereof
PT198964751T PT3893889T (pt) 2018-12-13 2019-12-12 Composto agonista do recetor e método de preparação e utilização do mesmo
KR1020257028884A KR20250133486A (ko) 2018-12-13 2019-12-12 THRβ 수용체 효능제 화합물 및 그의 제조 방법 및 용도
BR112021010871-8A BR112021010871A2 (pt) 2018-12-13 2019-12-12 Composto agonista do receptor thrb e método de preparação e uso do mesmo
LTEPPCT/US2019/066013T LT3893889T (lt) 2018-12-13 2019-12-12 Thrβ receptoriaus agonisto junginys ir jo gamybos ir panaudojimo būdai
JP2021533640A JP7532371B2 (ja) 2018-12-13 2019-12-12 Ｔｈｒβ受容体アゴニスト化合物、およびその製造方法および使用
TW114133235A TW202600541A (zh) 2018-12-13 2019-12-12 一種THRβ受體激動劑化合物及其製備方法和用途
PE2021000858A PE20211788A1 (es) 2018-12-13 2019-12-12 Compuesto agonista de receptor thrb y metodo de preparacion y uso del mismo
MX2021006908A MX2021006908A (es) 2018-12-13 2019-12-12 Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
ARP190103650A AR117694A1 (es) 2018-12-13 2019-12-12 COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO
US16/712,301 US11084802B2 (en) 2018-12-13 2019-12-12 THRβ receptor agonist compound and preparation method and use thereof
FIEP19896475.1T FI3893889T3 (fi) 2018-12-13 2019-12-12 Thrb-reseptoriagonistiyhdiste ja sen valmistusmenetelmä ja käyttö
EP19896475.1A EP3893889B8 (en) 2018-12-13 2019-12-12 Thrb receptor agonist compound and preparation method and use thereof
DK19896475.1T DK3893889T3 (da) 2018-12-13 2019-12-12 Thrb-receptoragonistforbindelse og fremgangsmåde til fremstilling og anvendelse deraf
FIEP25157448.9T FI4574821T3 (fi) 2018-12-13 2019-12-12 Thrb-reseptoriagonistiyhdiste ja sen valmistusmenetelmä ja käyttö
IL310699A IL310699B2 (en) 2018-12-13 2019-12-12 THR-Beta receptor agonist compound and method for its preparation and use
AU2019398339A AU2019398339C1 (en) 2018-12-13 2019-12-12 THRβ receptor agonist compound and preparation method and use thereof
PCT/US2019/066013 WO2020123827A1 (en) 2018-12-13 2019-12-12 Thrβ receptor agonist compound and preparation method and use thereof
CA3120880A CA3120880A1 (en) 2018-12-13 2019-12-12 Thrb receptor agonist compound and preparation method and use thereof
KR1020217021249A KR102905557B1 (ko) 2018-12-13 2019-12-12 THRβ 수용체 효능제 화합물 및 그의 제조 방법 및 용도
CN201980081797.3A CN113194958B (zh) 2018-12-13 2019-12-12 THRβ受体激动剂化合物及其制备方法和用途
SG11202106194TA SG11202106194TA (en) 2018-12-13 2019-12-12 Thrβ receptor agonist compound and preparation method and use thereof
MA054471A MA54471A (fr) 2018-12-13 2019-12-12 Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation
DK25157448.9T DK4574821T3 (da) 2018-12-13 2019-12-12 Thrb-receptoragonistforbindelse og fremgangsmåde til fremstilling og anvendelse deraf
IL283362A IL283362B2 (en) 2018-12-13 2019-12-12 THR-Beta RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF
TW108145594A TWI837244B (zh) 2018-12-13 2019-12-12 一種THRβ受體激動劑化合物及其製備方法和用途
LTEP25157448.9T LT4574821T (lt) 2018-12-13 2019-12-12 Thrβ receptoriaus agonisto junginys ir jo gamybos bei panaudojimo būdas
EP25157450.5A EP4529954A3 (en) 2018-12-13 2019-12-12 Thrb receptor agonist compound and preparation method and use thereof
MYPI2021002740A MY207657A (en) 2018-12-13 2019-12-12 Thr receptor agonist compound and preparation method and use thereof
US17/013,314 US11034676B2 (en) 2018-12-13 2020-09-04 THRB receptor agonist compound and preparation method and use thereof
MX2024003295A MX2024003295A (es) 2018-12-13 2021-06-10 Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
CL2021001521A CL2021001521A1 (es) 2018-12-13 2021-06-10 Compuesto agonista de receptor thrb y método de preparación y uso del mismo
CONC2021/0008817A CO2021008817A2 (es) 2018-12-13 2021-07-02 Compuesto agonista de receptor thrβ y método de preparación y uso del mismo
US18/315,291 US12338232B2 (en) 2018-12-13 2023-05-10 THRβ receptor agonist compound and preparation method and use thereof
JP2024124269A JP2024174860A (ja) 2018-12-13 2024-07-31 Ｔｈｒβ受容体アゴニスト化合物、およびその製造方法および使用
US19/052,553 US12365669B2 (en) 2018-12-13 2025-02-13 THRβ receptor agonist compound and preparation method and use thereof
US19/052,557 US12459926B2 (en) 2018-12-13 2025-02-13 THRβ receptor agonist compound and preparation method and use thereof
AU2025201590A AU2025201590A1 (en) 2018-12-13 2025-03-05 THRβ receptor agonist compound and preparation method and use thereof
US19/319,446 US20260001867A1 (en) 2018-12-13 2025-09-04 Thr beta receptor agonist compound and preparation method and use thereof
IL324507A IL324507A (en) 2018-12-13 2025-11-06 Thr-beta receptor agonist compound and method for its preparation and use
JP2025229427A JP2026035823A (ja) 2018-12-13 2025-12-04 Ｔｈｒβ受容体アゴニスト化合物、およびその製造方法および使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811527414.4A CN111320609A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511225496.7A Division CN121081472A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN111320609A true CN111320609A (zh) 2020-06-23

Family

ID=71071432

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201811527414.4A Pending CN111320609A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途
CN202511225496.7A Pending CN121081472A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途
CN201980081797.3A Active CN113194958B (zh) 2018-12-13 2019-12-12 THRβ受体激动剂化合物及其制备方法和用途
CN202310453989.0A Active CN116444498B (zh) 2018-12-13 2019-12-12 THRβ受体激动剂化合物及其制备方法和用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202511225496.7A Pending CN121081472A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途
CN201980081797.3A Active CN113194958B (zh) 2018-12-13 2019-12-12 THRβ受体激动剂化合物及其制备方法和用途
CN202310453989.0A Active CN116444498B (zh) 2018-12-13 2019-12-12 THRβ受体激动剂化合物及其制备方法和用途

Country Status (25)

Country Link
US (6) US11084802B2 (https=)
EP (3) EP3893889B8 (https=)
JP (3) JP7532371B2 (https=)
KR (2) KR102905557B1 (https=)
CN (4) CN111320609A (https=)
AR (1) AR117694A1 (https=)
AU (2) AU2019398339C1 (https=)
BR (1) BR112021010871A2 (https=)
CA (1) CA3120880A1 (https=)
CL (1) CL2021001521A1 (https=)
CO (1) CO2021008817A2 (https=)
DK (2) DK4574821T3 (https=)
ES (1) ES3064255T3 (https=)
FI (2) FI4574821T3 (https=)
HR (1) HRP20260358T1 (https=)
IL (3) IL310699B2 (https=)
LT (2) LT4574821T (https=)
MA (1) MA54471A (https=)
MX (2) MX2021006908A (https=)
MY (1) MY207657A (https=)
PE (2) PE20252338A1 (https=)
PT (1) PT3893889T (https=)
SG (1) SG11202106194TA (https=)
TW (3) TW202600541A (https=)
WO (1) WO2020123827A1 (https=)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909137A (zh) * 2019-05-10 2020-11-10 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
WO2022057845A1 (zh) * 2020-09-17 2022-03-24 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
CN114591300A (zh) * 2020-12-04 2022-06-07 南京圣和药业股份有限公司 作为THRβ激动剂的杂环化合物及其应用
WO2022127699A1 (zh) * 2020-12-15 2022-06-23 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
WO2022143574A1 (zh) 2020-12-30 2022-07-07 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
WO2023083288A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
CN116406356A (zh) * 2020-10-23 2023-07-07 马德里加尔制药公司 作为甲状腺激素类似物的中间体的6-(4-硝基-苯氧基)-2h-哒嗪-3-酮和6-(4-氨基-苯氧基)-2h-哒嗪-3-酮衍生物的制备方法
US11964964B2 (en) 2018-06-12 2024-04-23 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
WO2024120426A1 (zh) 2022-12-07 2024-06-13 昆药集团股份有限公司 一种甲状腺激素β受体激动剂、晶型、制备方法和用途
US12338232B2 (en) 2018-12-13 2025-06-24 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
WO2025162405A1 (zh) * 2024-02-01 2025-08-07 罗群 苯酚类衍生物及其医药用途
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
AU2021374988A1 (en) * 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists
PE20240097A1 (es) * 2021-03-03 2024-01-18 Terns Pharmaceuticals Inc Compuestos agonistas beta del receptor de la hormona tiroidea
CN119013027A (zh) 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
CA3252274A1 (en) * 2022-02-10 2023-08-17 Madrigal Pharmaceuticals, Inc. THR BETA ANALOGUES AND THEIR USES
JPWO2024143235A1 (https=) * 2022-12-26 2024-07-04
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist
US20260102403A1 (en) * 2024-10-11 2026-04-16 Aligos Therapeutics, Inc. Oral formulations of thr-beta agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228135A (zh) * 2005-07-21 2008-07-23 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197307A (en) 1977-04-12 1980-04-08 Ciba-Geigy Corporation 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
EP0377903A3 (de) 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
ES2240017T3 (es) 1999-09-30 2005-10-16 Pfizer Products Inc. Derivados de 6-azauracilo como ligandos de receptores tiroideos.
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
EP1347959A1 (de) 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
EP1471049A4 (en) * 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
GB0610322D0 (en) 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
WO2008130637A1 (en) 2007-04-18 2008-10-30 New York University Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
RU2527948C2 (ru) 2009-04-20 2014-09-10 Мицубиси Танабе Фарма Корпорейшн Новый агонист бета рецептора тиреоидного гормона
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
JP2011114768A (ja) 2009-11-30 2011-06-09 Panasonic Corp 複合無線装置
SG11201402004YA (en) 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102898377B (zh) * 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN105477636B (zh) 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11419878B2 (en) 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
SMT202500241T1 (it) 2016-03-31 2025-07-22 Genfit Elafibranor per uso nel trattamento di colangite biliare primitiva
BR112018073460A2 (pt) 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2018103624A1 (zh) 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018167103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7266531B2 (ja) 2017-04-18 2023-04-28 ジェンフィ エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
CN111032884A (zh) 2017-08-25 2020-04-17 基恩菲特公司 非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
EP3684954B1 (en) 2017-09-18 2025-11-26 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
EP3710599B1 (en) 2017-11-13 2024-07-17 Gilead Sciences, Inc. Method for staging liver fibrosis in nash patients
JP7156722B2 (ja) 2018-01-23 2022-10-19 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピリダジノン化合物
WO2019209738A1 (en) 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN112805005A (zh) 2018-08-24 2021-05-14 拓臻股份有限公司 甲状腺素受体β促效剂化合物
US11541745B2 (en) 2018-08-24 2023-01-03 Plastic Omnium Advanced Innovation And Research Assembly for a fluid tank comprising a baffle and a fluid transfer line passing through the baffle
EP3844156A4 (en) 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF HEPATIC DISORDERS
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
EA202190661A1 (ru) 2018-09-18 2021-08-13 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора для лечения заболевания
CA3113373A1 (en) 2018-10-12 2020-04-16 InventisBio Co., Ltd. Thyroid hormone receptor agonists
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN113474335B (zh) 2019-02-21 2024-12-03 南京瑞捷医药科技有限公司 化合物及其作为甲状腺激素受体激动剂的用途
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
EP4003349A1 (en) 2019-07-23 2022-06-01 Novartis AG Combination treatment of liver diseases using fxr agonists
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
TW202128668A (zh) 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
US20210379043A1 (en) 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
US20210379040A1 (en) 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
AU2021359895A1 (en) 2020-10-15 2023-06-15 Eli Lilly And Company Polymorphs of an fxr agonist
CN114437034A (zh) 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
PE20240097A1 (es) 2021-03-03 2024-01-18 Terns Pharmaceuticals Inc Compuestos agonistas beta del receptor de la hormona tiroidea
WO2022194278A1 (zh) 2021-03-19 2022-09-22 南京明德新药研发有限公司 双环苯酚类化合物及其应用
CN119013027A (zh) 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
PE20241327A1 (es) 2021-11-11 2024-06-26 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-beta
WO2023220404A1 (en) 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228135A (zh) * 2005-07-21 2008-07-23 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTHA J. KELLY等: "Discovery of [3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor B Agonist in Clinical Trials for the Treatment", 《J.MED.CHEM.》, 8 April 2014 (2014-04-08), pages 3912 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358899B2 (en) 2018-06-12 2025-07-15 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
US11964964B2 (en) 2018-06-12 2024-04-23 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
US12459926B2 (en) 2018-12-13 2025-11-04 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
US12365669B2 (en) 2018-12-13 2025-07-22 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
US12338232B2 (en) 2018-12-13 2025-06-24 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
CN111909137A (zh) * 2019-05-10 2020-11-10 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
JP2023543711A (ja) * 2020-09-17 2023-10-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 甲状腺ホルモンβ受容体アゴニストとしての化合物及びその使用
JP7771173B2 (ja) 2020-09-17 2025-11-17 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 甲状腺ホルモンβ受容体アゴニストとしての化合物及びその使用
WO2022057845A1 (zh) * 2020-09-17 2022-03-24 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN116406356A (zh) * 2020-10-23 2023-07-07 马德里加尔制药公司 作为甲状腺激素类似物的中间体的6-(4-硝基-苯氧基)-2h-哒嗪-3-酮和6-(4-氨基-苯氧基)-2h-哒嗪-3-酮衍生物的制备方法
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
CN114591300A (zh) * 2020-12-04 2022-06-07 南京圣和药业股份有限公司 作为THRβ激动剂的杂环化合物及其应用
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
WO2022127699A1 (zh) * 2020-12-15 2022-06-23 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
WO2022143574A1 (zh) 2020-12-30 2022-07-07 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
WO2023083288A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
WO2024120426A1 (zh) 2022-12-07 2024-06-13 昆药集团股份有限公司 一种甲状腺激素β受体激动剂、晶型、制备方法和用途
EP4631943A1 (en) 2022-12-07 2025-10-15 Kpc Pharmaceuticals, Inc THYROID HORMONE ß RECEPTOR AGONIST, CRYSTAL FORM, PREPARATION METHOD AND USE
WO2025162405A1 (zh) * 2024-02-01 2025-08-07 罗群 苯酚类衍生物及其医药用途

Also Published As

Publication number Publication date
KR20250133486A (ko) 2025-09-05
SG11202106194TA (en) 2021-07-29
US20250179053A1 (en) 2025-06-05
WO2020123827A1 (en) 2020-06-18
LT3893889T (lt) 2026-04-10
TWI837244B (zh) 2024-04-01
US11034676B2 (en) 2021-06-15
IL310699B1 (en) 2025-12-01
CA3120880A1 (en) 2020-06-18
EP4529954A2 (en) 2025-04-02
AU2019398339C1 (en) 2025-08-21
TW202039470A (zh) 2020-11-01
JP2024174860A (ja) 2024-12-17
CN116444498A (zh) 2023-07-18
US20230278988A1 (en) 2023-09-07
EP3893889B1 (en) 2026-01-28
US12459926B2 (en) 2025-11-04
PE20211788A1 (es) 2021-09-09
US20250179054A1 (en) 2025-06-05
PE20252338A1 (es) 2025-10-02
ES3064255T3 (en) 2026-04-23
US20200399249A1 (en) 2020-12-24
MX2021006908A (es) 2021-07-07
AU2025201590A1 (en) 2025-03-20
JP2026035823A (ja) 2026-03-04
CN113194958B (zh) 2023-05-23
IL283362B1 (en) 2024-03-01
KR20210102328A (ko) 2021-08-19
US11084802B2 (en) 2021-08-10
EP4574821B1 (en) 2026-02-04
IL310699A (en) 2024-04-01
HRP20260358T1 (hr) 2026-04-24
JP7532371B2 (ja) 2024-08-13
EP3893889A1 (en) 2021-10-20
TWI899867B (zh) 2025-10-01
US20260001867A1 (en) 2026-01-01
US12338232B2 (en) 2025-06-24
EP4574821B8 (en) 2026-03-18
CO2021008817A2 (es) 2021-07-19
IL324507A (en) 2026-01-01
EP4529954A3 (en) 2025-06-25
CN113194958A (zh) 2021-07-30
IL310699B2 (en) 2026-04-01
FI3893889T3 (fi) 2026-03-24
FI4574821T3 (fi) 2026-03-25
US12365669B2 (en) 2025-07-22
US20200190064A1 (en) 2020-06-18
BR112021010871A2 (pt) 2021-08-31
AR117694A1 (es) 2021-08-25
EP4574821A1 (en) 2025-06-25
LT4574821T (lt) 2026-04-10
DK3893889T3 (da) 2026-03-02
EP3893889A4 (en) 2022-08-03
TW202440551A (zh) 2024-10-16
TW202600541A (zh) 2026-01-01
CL2021001521A1 (es) 2022-01-28
PT3893889T (pt) 2026-03-16
CN121081472A (zh) 2025-12-09
CN116444498B (zh) 2025-06-06
KR102905557B1 (ko) 2025-12-31
IL283362A (en) 2021-07-29
AU2019398339A1 (en) 2021-06-10
DK4574821T3 (da) 2026-03-02
AU2019398339B2 (en) 2024-12-05
MX2024003295A (es) 2024-04-16
EP3893889B8 (en) 2026-03-18
MY207657A (en) 2025-03-10
JP2022512482A (ja) 2022-02-04
MA54471A (fr) 2021-10-20
IL283362B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CN111320609A (zh) 一种THRβ受体激动剂化合物及其制备方法和用途
CN111647000B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
HK40032089A (en) THRβ RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF
HK40058240A (en) Thrβ receptor agonist compound and preparation method and use thereof
RU2809040C2 (ru) АГОНИСТ РЕЦЕПТОРОВ THRβ И СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
HK40058240B (en) Thrβ receptor agonist compound and preparation method and use thereof
HK40127942A (en) Thrb receptor agonist compound and preparation method and use thereof
BR122023027289A2 (pt) COMPOSTO AGONISTA DO RECEPTOR THRbeta, SEUS USOS, E COMPOSIÇÃO FARMACÊUTICA
HK40029463A (en) Pyrazine derivative and application thereof in inhibiting shp2
HK40029463B (en) Pyrazine derivative and application thereof in inhibiting shp2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032089

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20260303

Address after: California, USA

Applicant after: Tuozhen pharmaceutical Co.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Tuozhen Co.,Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right